Xeris Pharmaceuticals | XERS - Operating Profit



Xeris Pharmaceuticals reported $4.48M in Operating Profit for its fiscal quarter ending in June of 2025.


Operating Profit Change Date
Adcock Ingram Holdings ZAR 487.33M 8.25M Dec/2024
Celltrion KRW 242.47B 94.87B Jun/2025
Cspc Pharmaceutical CNY 1.79B 940.51M Mar/2025
Dianthus Therapeutics USD -34927000 3.01M Jun/2025
Divis Laboratories Ltd 6.17B 1.62B Jun/2025
Eli Lilly USD 7.02B 1.61B Jun/2025
Kangmei Pharma CNY 16.43M 3.34M Jun/2025
Knight Therapeutics CAD 3.2M 1.29M Sep/2024
Laboratorios Farma EUR 27.37M 95.7M Jun/2025
Malin Corporation EUR -1100000 400K Dec/2024
Medical Developments International AUD 182K 20.42M Dec/2024
Neuren Pharmaceuticals AUD 176.69M 166.79M Dec/2024
Organigram Holdings CAD -2100000 9.2M Jun/2025
Pacira USD 10.23M 8.24M Jun/2025
Perrigo USD 55.6M 23.8M Jun/2025
Pharma Mar EUR 24.11M 27.19M Jun/2025
Qiagen NV USD 135.97M 10.81M Jun/2025
Sartorius EUR 161.8M 24.4M Jun/2025
Sino Biopharmaceutical CNY 1.33B 2.53B Dec/2024
Supernus Pharmaceuticals USD 12.14M 14.74M Jun/2025
Tilray USD -42218000 5.65M Nov/2024
Zz Pientze Pharmaceu 553.87M 632.12M Jun/2025